Cost Differential of Chemotherapy for Solid Tumors

Area of Science:

• Oncology
• Health Economics

Background:

• Chemotherapy represents a substantial part of national cancer expenditures.
• Current National Comprehensive Cancer Network (NCCN) guidelines for solid tumors lack cost-effectiveness data for treatment strategies.

Purpose of the Study:

• To analyze the cost differentials among various chemotherapy regimens for common solid tumors.
• To evaluate the economic implications of different chemotherapeutic approaches.

Main Methods:

• Acquired chemotherapy regimens and dosages from 2013 NCCN guidelines for bladder, breast, colon, and lung cancers.
• Calculated baseline drug and treatment costs using 2013 Medicare Part B average sales price (ASP) data.
• Extrapolated costs for a 6-month treatment duration for an average US adult male.

Main Results:

• The 6-month mean chemotherapy cost was $26,989, with a median of $9,611.
• Metastatic cancer therapy regimens ($35,315) were significantly more expensive than curative therapy regimens ($18,107).
• Regimens utilizing biologics ($77,278) were substantially more costly than those without ($13,646), with cost differences reaching $90,843.

Conclusions:

• Significant cost variations exist between chemotherapy regimens for common solid tumors.
• Integrating cost and incremental effectiveness into NCCN guidelines could foster more economically responsible clinical practices.